The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcoma.

ABSTRACT:

Background

The analysis of tumor DNA by whole-genome sequencing (WGS) is increasingly utilized for the identification of clinically relevant DNA aberrations. We aim to assess whether WGS improves the guidance of individualized systemic therapy in soft tissue sarcoma (STS).

Patients and methods

WGS results of STS patients were retrieved from electronic patient records and pathology reports from clinical studies and routine diagnostics. WGS was carried out in primary STS with an unfavorable prognosis, metastatic STS, or STS where broad molecular diagnostics were deemed necessary. Actionable targets were defined as genomic alterations identified by WGS for which specific systemic therapy was indicated in routine care or clinical trials available at time of the WGS analysis.

SUBMITTER: van der Laan P 

PROVIDER: S-EPMC12192325 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature